Alvotech

Róbert Wessman founded Alvotech on January 1, 2013, in Reykjavik, Gullbringusysla, Iceland with the purpose of enhancing patients' health and quality of life throughout the world by extending access to effective medicines for a variety of conditions. It is a fully integrated specialty biopharmaceutical firm dedicated solely to the discovery and production of high-quality biosimilar medicines.

Biosimilars are medical products that are highly similar to an already approved biological medicine, known as the reference product. As a pharmaceutical company that develops and manufactures biosimilar drugs, Alvotech's focus is on developing high-quality biosimilar drugs that are more affordable and accessible to patients in need of treatment for various conditions such as arthritis, cancer, and diabetes. The company has a strong pipeline of biosimilar drugs and aims to improve patient access to life-saving medicines globally.

As of April 2023, Alvotech has a market cap of $2.63 Billion, making it the second-biggest company in Iceland. The latest financial reports show that the company's current revenue (TTM) is $77.67 million. In 2021, Alvotech generated revenue of $36.77 million, which is a decrease compared to the previous year's revenue of $66.61 million. Currently, the company operates in five locations and employs approximately 1000 people.

Founded: Jan 1, 2013
Headquarters: Reykjavik, Iceland
Website: https://alvotech.com